๐ฐ Classification Committee News
Page 5 - Classification Committee News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Classification Committee. Real-time updates on events, politics, business and more.
September 9, 2022
Comprehensive “2022” overview of acute and preventive treatments for the management of chronic migraine in youth. Click to read more..
August 19, 2022
Elsa Matthee is stepping down as chair of the Boccia International Sport Federation Classification Committee, having led the panel for more than 20 years.
June 29, 2022
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start of treatment.
June 26, 2022
Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVYยฎ (fremanezumab) - read this article along with other careers information, tips and advice on BioSpace
June 24, 2022
Interim data presented at the European Academy of Neurology 2022 shows that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more over the six-month period from the start
June 24, 2022
Press release content from Business Wire. The AP news staff was not involved in its creation.
June 21, 2022
- Submission is based on pivotal Phase 3 PROGRESS chronic migraine study evaluating atogepant (QULIPTATM) in adult patients that met primary endpoint of...
June 8, 2022
To address wage compression caused by the University System of Maryland raising its minimum wage to $15, the system is planning to adjust nonexempt staff pay scales. Nonexempt, hourly positions within the USM are sorted into โpay gradeโ categories that denote the minimum amount that role can be paid, the maximum it can be paid, and ...
May 5, 2022
World Taekwondo's Classification Committee chair Hadwah Abdelmatloub Moawad has revealed plans to train more classifiers, with the aim of expanding the sport of Para-taekwondo.
March 10, 2022
NORTH CHICAGO, Ill., March 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the Phase 3 PROGRESS trial evaluating atogepant (QULI...